Plain-English translation of NCT05913674 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a modified approach to early post-operative intraperitoneal chemotherapy (mEPIC), which delivers Fluorouracil—a chemotherapy drug—directly into the abdomen shortly after surgery to remove cancer. The goal is to eliminate any remaining cancer cells on the abdominal surfaces before scar tissue forms, potentially improving survival and reducing cancer recurrence. This treatment is being tested in patients whose colorectal or appendiceal cancer has spread to the peritoneum (the lining of the abdomen).
Even after surgery removes all visible cancer from the abdomen, microscopic cancer cells can remain on the abdominal surfaces and may recur. This trial exists to see whether delivering chemotherapy directly into the abdomen in the days right after surgery—before scarring occurs—can help prevent this recurrence and improve long-term survival outcomes.
You likely qualify if…
You likely don't qualify if…
If you qualify and enroll, you will first have imaging tests (CT scans and possibly a PET scan) and a diagnostic procedure to confirm the extent of cancer spread. You will then undergo surgery to remove as much cancer as possible from your abdomen, followed immediately by a heated chemotherapy wash inside the abdomen. On days 1 and 2 after surgery, you will receive the modified chemotherapy treatment (mEPIC) through tubes left in your abdomen. You will remain hospitalized during this time for close monitoring and care.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
Canada